Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Research Associate, AAV Process Development

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
May 12, 2022

View more

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How You Will Achieve MoreAtIntellia:

Do you have experiencein viral vector process developmentor process engineering and are interested in an opportunity to help bring AAVtechnologyto a leading genome editing company using CRISPR-Cas9?Are you passionate about playing a key role in deepening our product understanding through characterization to optimize the production process and evaluate/implement improvements?

This Senior Research Associate role supports Intelliadevelopment candidates in therapeutic gene therapy programs acrossourin vivoandex vivoproduct pipelinesby assisting in the development of an AAV upstream platform for use in preclinical and clinical gene therapy studies. The ideal candidate isa motivated self-starterwith high scientific integrityand a solid foundation in process engineering from which to grow. You should be ready to help drive platform development strategy for upstream processes considering robustness, scalability and manufacturing feasibility/suitability. You should behighly motivated and passionate to work in a fast-pacedand growingenvironment andbe a team playerwith an eye for continuous improvement.Key responsibilities include:

  • Experience with suspensionHEK293 cell culture, aseptic technique, and understanding of biochemical engineering concepts.

  • Experience with viral vector, and transient transfection production systems.

  • Experience with various upstream bioreactor platforms, as well as high-throughput platforms (e.g. Ambr15), bench scale, and bioreactors from 2 L to 200 L.

  • Ability to use relevant software packages for statistical analysis and experimental design including DoE.

  • Perform AAV analytics including ELISA andddPCRto support in-process analytics in PD’s activities.

About You:

Are you a motivated and creative individual with experience in AAV bioprocessing willing to help develop viral vector upstream production platforms and are awell-organized and detail-orientedself-starter with a strong team-player mindset andability to juggle multiple tasks and work in a fast-paced environment?Have you demonstrated excellent aseptic cell culture technique,including, transfection, developmentandmaintenance ofcell lines and their inventoryall with high attention to detail, and possess the following?

  • BS in Chemical/Biochemical Engineering, Biochemistry, Molecular Biology, or relevant disciplines with minimal 2 years of relevant industrial experiences; or MS in Chemical/Biochemical Engineering, Biochemistry, Molecular Biology, or relevant disciplines

  • Proficiency in operation of bioreactors and single-use technology, a solid understanding of the principles of scale-up and optimization of process parameters for mammalian cell culture required.

  • Experience in operating ambr15, ambr250, and 2L bioreactors is highly preferred. Experience in operating routine cell culture analyzers is required.

  • Prior experience with clarification techniques such as depth filtration and purification/concentration techniques (ultrafiltration/diafiltration) and understanding of the parameters that impact these steps, is a plus.

  • Understanding of AAV analytics (ddPCR, ELISA, CE-SDS, AUC)in support of product characterization is preferred

  • Proficient in MS Office; knowledge of tools such asArxspan,SmartSheets,Benchlingis highly desirable

  • Prior demonstrated experience in AAV development and understanding of AAV biology as well as gene therapy is highly desirable

Find your next long-term growth opportunity with us!

Meet your future team:

In this role, you will be part of the AAVUpstream Process Developmentteamreporting to the Upstream leadand play a key role in platform fit, process optimization, scale-up and tech transfer for clinical manufacturing as well as late-stage activities such as process characterization.Your team is apart of the broaderAAVProcess Developmentorganization, thus from this vantage point, you will participate in andsupport multiple activities in the product developmentlifecycle and AAV PD team activities yetbe a keymember of ateam accountable for upstream development workflow improvement.You will join the growing,collaborativeand passionate Tech Ops teamaswe advance ourtherapeuticpipeline products using CRISPR genome-editing technologies.We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert